SCHEMBL8934795

SCHEMBL8934795

O=c1[nH]ccc2cc(OC3CCN(Cc4ccc(Cl)cc4Cl)CC3)ccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 13/20 0.55
ROCK2 O75116 2/20 0.55
PRKCD Q05655 2/20 0.55
PRKACA P17612 1/20 0.55
PRKG1 Q13976 1/20 0.55
PKN1 Q16512 1/20 0.55
PKN2 Q16513 1/20 0.55
AAK1 Q2M2I8 1/20 0.55
CDC42BPA Q5VT25 1/20 0.55
Q6ZSR9 Q6ZSR9 1/20 0.55
BMP2K Q9NSY1 1/20 0.55
CDC42BPB Q9Y5S2 1/20 0.55
PRKX P51817 1/20 0.49
PRKCE Q02156 1/20 0.49
PRKD1 Q15139 1/20 0.49
EPHX2 P34913 4/20 0.46
MAOA P21397 2/20 0.46
MAOB P27338 2/20 0.46
CYP2C9 P11712 2/20 0.43
CYP2J2 P51589 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8938636 0.90 ROCK1 (0.53) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL8934780 0.89 ROCK1 (0.56) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL8936199 0.89 ROCK1 (0.51) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL8934763 0.88 ROCK1 (0.60) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL8934976 0.86 MAP2K1 (0.56) ROCK1ROCK2EPHX2CYP2C9CYP2J2
SCHEMBL8934812 0.85 ROCK1 (0.58) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL8934776 0.84 MAOA (0.61) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL8937948 0.84 ROCK1 (0.52) ROCK1EPHX2
SCHEMBL8935171 0.83 ROCK1 (0.51) ROCK1EPHX2MAOAMAOBCYP2C9
SCHEMBL4005889 0.83 ROCK1 (0.61) ROCK1ROCK2PRKCDPRKACAPRKG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385047-B1 Piperidinyl-substituted isoquinolone derivatives SANOFI SA (FR) 2013-05-29 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 ROCK1 8/4885ROCK2 10/4885PRKCD 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.